Dallas, Texas 03/19/2014 (FINANCIALSTRENDS) – Dendreon Corporation (NASDAQ:DNDN) main product line is the 2010-launched Provenge, which was the first drug to be approved for this class of prostate cancer treatment. This drug’s efficacy has always precededit’s use as an immunology drug. Other drugs in this category soon followed, given the success of this drug. ImmunoGen’sKadcyla, whichhas proven efficacy in treating breast cancer in the recent times, is one of the latter type of drugs.
Dendreon Corporation(NASDAQ:DNDN) will in the future have to contend with another cancer-fighting therapy called Multikine,currently under development by another drug maker called CEL-SCI Corporation. Why is Multikine, expected to be different from other drugs in this category? CEL-SCI is known to be using the immune system of the patient itself to develop indices and fight the disease. Besides, this line of product is definitely different from the existing products which also relate to radiation as well as chemotherapy.
Unlike Dendreon Corporation(NASDAQ:DNDN), Multikine is expected to use the existing as well as yet to be expressed immune system of the individual to recognize the cancer causatives and eventually fight it.
However, it cannot be denied that Dendreon Corporation(NASDAQ:DNDN)’s Provenge is the best in class. It is another fact that there have been no outstanding sales figures for such a successful drug. Provenge has been unequivocally proved that this drug is the best in bringing out the highest potential of immunity in a person. The cost of Provenge, which remains outside the reach of the less endowed patients, is the challenge.
So, will 2014 prove to be a year which will be the break-even financial year for one of the most successful immunology-based cancer fighting drugs is the puzzle? With other less expensive drugs likely to be available; will Provenge, survive and continue to rule the immunology drug therapy roost or make way for the next best cancer-fighting drug.